Posts tagged as

Prostate Cancer

A Message from Dr. Nancy Mendenhall – Spring/Summer 2023

Dear COMPPARE team, participants, stakeholders and friends, From the moment enrollment was completed on October 31, 2022 we have turned our focus to retention, and I am pleased to report that retention (keeping patients actively on a study) and data collection rates have been excellent. I am immensely grateful…

COMPPARE Newsletter: Summer 2023

A Message from Dr. Nancy Mendenhall Since COMPPARE was launched in 2017, new information has emerged that suggests there may be other differences in outcomes between photon and proton radiation in prostate cancer. We would like to answer as many of these questions as…

Newsroom

COMPPARE Newsroom Prostate cancer research news…

A Message from Dr. Nancy Mendenhall – Fall/Winter 2022-23

Dear COMPPARE team, participants, stakeholders and friends, I am excited to share with you that on October 31, 2022, COMPPARE closed enrollment with a total of 2,524 participants (1,024 photon patients and 1,500 proton patients; 900 pragmatic, 600 randomized)! This is an exceptional accomplishment given the ongoing national healthcare…

COMPPARE Newsletter: Fall/Winter 2022-23

A Message from Dr. Nancy Mendenhall I am excited to share with you that on October 31, 2022, COMPPARE closed enrollment with a total of 2,524 participants (1,024 photon patients and 1,500 proton patients; 900 pragmatic, 600 randomized)! Read Dr. Mendenhall’s message.   Partner Site…

COMPPARE Enrolls 1,000th Photon Patient

The COMPPARE Coordinating Center announced today that the study has enrolled its 1,000th photon prostate cancer patient to reach 67% of its photon cohort goal. COMPPARE Partner Site University of Maryland enrolled the 1,000th patient, followed closely by UNC REX Healthcare, Raleigh, NC, which…

A Message from Dr. Nancy Mendenhall – Spring/Summer 2022

Dear COMPPARE team, participants, stakeholders and friends, I am pleased to announce that on May 3, 2022, UH Seidman Cancer Center enrolled our 2,250th COMPPARE participant! This means we are now 75% of the way through the accrual process, an exceptional accomplishment given the ongoing challenges…

COMPPARE Newsletter: Spring/Summer 2022

A Message from Dr. Nancy Mendenhall As we near the completion of COMPPARE’s overall enrollment objective – a total of 3,000 patients – we are beginning to reflect and evaluate what we’ve learned thus far in creating and carrying out a large, multi-institutional pragmatic…

COMPPARE Enrolls 1,500th Proton Patient, Reaches Cohort Goal

The COMPPARE Coordinating Center announced today that the study has enrolled its 1,500th proton prostate cancer patient and has closed enrollment for the proton cohort. This goal was achieved in advance of the projected completion date of July 31, 2022. The proton cohort is divided into two groups: Pragmatic and…

COMPPARE Achieves 75% Enrollment Milestone

The COMPPARE Coordinating Center announced today that the study achieved 75% enrollment on May 3, 2022. COMPPARE realized both a remarkable overall accrual rate and a exceptional accrual rate of minorities, despite the ongoing challenges presented by COVID-19. In fact, the study stands to become a model for patient-centric clinical…